While still in clinical trials, these tests are seen to be much closer to clinical use than previously thought, and are expected to complement, rather than replace, current cancer detection options. This was the outlook a year ago. So, where do we stand today? How close are we to having these tests available?
In this article series, the Munich Re medical team examines recent innovations in the field of medicine that are of particular interest to life and disability insurance carriers. Today we focus on new therapies for the treatment of HIV.
The Galleri test, through a simple blood draw, has the capability to detect a signal shared by more than 50 cancer types and predict the tissue type or organ associated with the signal to help healthcare providers determine next steps.
Long COVID – Into the Third Year, authored by Munich Re’s Dr. Tim Meagher, was recently published in the Journal of Insurance Medicine. The article provides an update on long Covid, with a particular focus on disease prevalence, disability and risk factors. It also discusses the longer-term outlook for individuals with long Covid.
In this article series, the Munich Re medical team examines recent innovations in the field of medicine that are of particular interest to life and disability insurance carriers. The first topic is the new drugs capturing headlines for their promise in the treatment of obesity.
With the advent of new screening programs for high risk adults with a previous smoking history, more than a million new cases of pulmonary nodules are found, with approximately a five percent malignancy rate. It is no wonder underwriters and physicians take these findings seriously, and a thorough work-up is done to be sure any nodule encountered has a benign outcome.
By using multi-cancer early detection, GRAIL’s Galleri® test can improve the health and longevity of policyholders with an elevated cancer risk
Much of the available data regarding the therapeutic use of psychedelics for mental health disorders remains introductory; however, momentum is building with the potential to offer unique treatments for many complex mental health disorders.
New pharmaceuticals to treat sickle cell disease (SCD) are steadily improving the health and wellbeing of many people living with this chronic disorder. It is hoped that revolutionary gene therapies now in clinical trials will be able to cure more SCD patients. The resulting improvements in morbidity and mortality rates could allow insurers to offer cover more widely and at more favorable terms for people living with SCD.
Prostate cancer is a significant disease—approximately 10 percent of men will be diagnosed with prostate cancer in their lifetime and the lifetime risk of dying of the disease is three percent.